StonvexLoading…
StonvexStonvexStonvexCore line items from CDXS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $70.39M | $59.34M | $70.14M | $138.59M |
Operating Income | $-41.74M | $-58.52M | $-68.07M | $-34.88M |
Net Income | $-43.97M | $-65.28M | $-76.24M | $-33.59M |
EPS (Diluted) | $-0.50 | $-0.89 | $-1.12 | $-0.51 |
Total Assets | $147.80M | $149.01M | $136.56M | $250.39M |
Total Liabilities | $97.27M | $82.08M | $49.95M | $105.60M |
Cash & Equivalents | $50.79M | $19.26M | $65.12M | $113.98M |
Free Cash Flow OCF − CapEx | $-23.85M | $-53.72M | $-57.06M | $2.98M |
Shares Outstanding | 90.48M | 81.85M | 69.91M | 65.81M |